Who is sponsoring NCT05300958?

NCT05300958 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT05300958?

Interventions in NCT05300958: Deferoxamine Plus Chemotherapy.

What condition does NCT05300958 study?

NCT05300958 studies Triple Negative Breast Cancer.

Is NCT05300958 still recruiting?

NCT05300958 is currently terminated. Last updated 22 July 2025.

Last reviewed 2025-07-22 · How we verify

NCT05300958

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer

Terminated Phase 2 Last updated 22 July 2025

What this trial tests

Phase 2 trial testing Deferoxamine Plus Chemotherapy in Triple Negative Breast Cancer in 25 participants. Terminated before completion.

Timeline

21 March 2022

Primary endpoint
21 July 2025

21 July 2025

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	21 March 2022
Primary completion	21 July 2025
Estimated completion	21 July 2025
Sites	1 location across China

Drugs / interventions tested

Deferoxamine Plus Chemotherapy — full drug profile →

Conditions studied

Triple Negative Breast Cancer — all drugs for Triple Negative Breast Cancer →

Sponsor

Sun Yat-sen University

Who can join

Adults 18 to 70, female only, with Triple Negative Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of the study is to evaluate the efficacy and safety of chemotherapy plus deferoxamine in metastatic breast cancer whose evaluation is stable disease with a trend of progression.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Ferroptosis in cancer: From molecular mechanisms to therapeutic strategies.
Zhou Q, Meng Y, Li D, Yao L, et al · · 2024 · cited 439× · PMID 38453898 · DOI 10.1038/s41392-024-01769-5
Interplay of Ferroptosis and Cuproptosis in Cancer: Dissecting Metal-Driven Mechanisms for Therapeutic Potentials.
Wang J, Li J, Liu J, Chan KY, et al · · 2024 · cited 33× · PMID 38339263 · DOI 10.3390/cancers16030512
Ferroptosis and endoplasmic reticulum stress in rheumatoid arthritis.
Ao Q, Hu H, Huang Y. · · 2024 · cited 25× · PMID 39076977 · DOI 10.3389/fimmu.2024.1438803
Lipotoxicity, lipid peroxidation and ferroptosis: a dilemma in cancer therapy.
Ma C, Hu H, Liu H, Zhong C, et al · · 2025 · cited 17× · PMID 40285867 · DOI 10.1007/s10565-025-10025-7
Molecular Insights on Signaling Cascades in Breast Cancer: A Comprehensive Review.
Panda VK, Mishra B, Mahapatra S, Swain B, et al · · 2025 · cited 17× · PMID 39858015 · DOI 10.3390/cancers17020234
The Present and Future of Clinical Management in Metastatic Breast Cancer.
Lin PH, Laliotis G. · · 2022 · cited 14× · PMID 36233758 · DOI 10.3390/jcm11195891
Targeting the initiator to activate both ferroptosis and cuproptosis for breast cancer treatment: progress and possibility for clinical application.
Imam M, Ji J, Zhang Z, Yan S. · · 2024 · cited 7× · PMID 39867656 · DOI 10.3389/fphar.2024.1493188
Tumoroid Model Reveals Synergistic Impairment of Metabolism by Iron Chelators and Temozolomide in Chemo-Resistant Patient-derived Glioblastoma Cells.
Amereh M, Seyfoori A, Shojaei S, Lane S, et al · · 2025 · cited 3× · PMID 40285641 · DOI 10.1002/advs.202412505

Verify or expand the search:

Other recruiting trials for Triple Negative Breast Cancer

Currently open trials in the same condition.

NCT07533123 — A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who H · Phase 3 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07340541 — Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies · Phase 2 · recruiting
NCT07281976 — A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer · Phase 1, PHASE2 · recruiting
NCT06225505 — Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE) · NA · recruiting

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05300958 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 22 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05300958.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing